Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia

Haematologica

Volumn 95, Issue 2, 2010, Pages 241-246

  Burmeister, Thomas ^a   Gökbuget, Nicola ^b   Schwartz, Stefan ^a   Fischer, Lars ^a   Hubert, Daniela ^a   Sindram, Annette ^a   Hoelzer, Dieter ^b   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Common ALL; Core binding factor; Helix loop helix transcription factor; Homeobox gene; Pre B ALL

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CD33 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TENIPOSIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TCF3; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GERMANY; GROUPS BY AGE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRE B LYMPHOCYTE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; CELL LINE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 76549104445     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011346     Document Type: Article

References (46)

1. Carroll AJ, Crist WM, Parmley RT, Roper M, Cooper MD, Finley WH. Pre-B cell leukemia associated with chromosome translocation 1;19. Blood. 1984;63(3):721-4.
2. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood. 1991;77(4): 687-93.
3. Kamps MP. E2A-Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation. Curr Top Microbiol Immunol. 1997;220:25-43.
4. Romana SP, Le Coniat M, Berger R. t(12;21): a new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer. 1994;9(3):186-91.
5. Romana SP, Mauchauffé M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995;85(12):3662-70.
6. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 1995; 92(11):4917-21.
7. de Bruijn MF, Speck NA. Core-binding factors in hematopoiesis and immune function. Oncogene. 2004;23(24):4238-48.
8. Niebuhr B, Fischer M, Täger M, Cammenga J, Stocking C. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis. 2008; 40(2):211-8.
9. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005; 15(3):162-74.
10. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-48.
11. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92(6):1898-909.
12. Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, et al. Atypical BCRABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica. 2007; 92(12):1699-702.
13. Schwartz S, Rieder H, Schläger B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24-)/CD65s(+) /CD15(+) B-cell phenotype. Leukemia. 2003;17(8):1589-95.
14. Andersson A, Höglund M, Johansson B, Lassen C, Billström R, Garwicz S, et al. Paired multiplex reverse-transcriptase polymerase chain reaction (PMRT-PCR) analysis as a rapid and accurate diagnostic tool for the detection of MLL fusion genes in hematologic malignancies. Leukemia. 2001; 15(8):1293-300.
15. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-28.
16. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-57.
17. Rosenfeld C, Goutner A, Venuat AM, Choquet C, Pico JL, Dore JF, et al. An effect human leukaemic cell line: Reh. Eur J Cancer. 1977;13(4-5):377-9.
18. Gleissner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCRABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536-43.
19. Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116-23.
20. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Groupe Français de Cytogénétique Hématologique. Blood. 1996;87(8):3135-42.
21. Martín Ramos ML, Lahuerta Palacios JJ, Martínez López J, Gómez Rodríguez MJ, Moreno Izquierdo A, Barreiro Miranda E. Karyotype and prognosis in adult Spanish acute lymphoblastic leukemia. Haematologica. 2001;86(4):438-9.
22. Khalidi HS, O'Donnell MR, Slovak ML, Arber DA. Adult precursor-B acute lymphoblastic leukemia with translocations involving chromosome band 19p13 is associated with poor prognosis. Cancer Genet Cytogenet. 1999;109(1):58-65.
23. Picard C, Hayette S, Bilhou-Nabera C, Cayuela JM, Delabesse E, Frenoy N, et al. Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. Leukemia. 2006; 20(12):2178-81.
24. Foà R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L, et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol. 2003;120(3):484-7.
25. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, et al. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006;20(12):2155-61.
26. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1990;76(1):117-22.
27. Chessels JM, Swansbury GJ, Reeves B, Bailey CC, Richards SM. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol. 1997;99(1):93-100.
28. Kager L, Lion T, Attarbashi A, Koenig M, Strehl S, Haas OA, et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica. 2007;92(11):1561-4.
29. Carroll WL, Bhojwani D, Dong-Joon M, Raetz E, Relling M, Davies S, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003;102-31.
30. Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia. 2009; 23(8):1406-9.
31. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360(26):2730-41.
32. Yuki Y, Imoto I, Imaizumi M, Hibi S, Kaneko Y, Amagasa T, et al. Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13). Cancer Sci. 2004;95(6):503-7.
33. Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, et al. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia. 2005;19(5):806-13.
34. Secker-Walker LM, Berger R, Fenaux P, Lai JL, Nelken B, Garson M, et al. Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. Leukemia. 1992;6(5):363-9.
35. Pui CH, Raimondi SC, Hancock ML, Rivera GK, Ribeiro RC, Mahmoud HH, et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol. 1994; 12(12):2601-6.
36. Sharma P, Watson N, Sartor M, McCowage G, Smith A. Fifteen cases of t(1;19) (q23;p13.3) identified in an Australian series of 122 children and 80 adults with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2001;124(2):132-6.
37. Shih LY, Chou TB, Liang DC, Tzeng YS, Rubnitz JE, Downing JR, et al. Lack of TELAML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan. Leukemia. 1996;10(9):1456-8.
38. Aguiar RC, Sohal J, van Rhee F, Carapeti M, Franklin IM, Goldstone AH, et al. TELAML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol. 1996;95(4):673-7.
39. Jabber Al-Obaidi MS, Martineau M, Bennett CF, Franklin IM, Goldstone AH, Harewood L, et al. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia. 2002;16(4):669-74.
40. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood. 1997;89(4): 1143-6.
41. Uckun FM, Pallisgaard N, Hokland P, Navara C, Narla R, Gaynon PS, et al. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42(1-2):41-56.
42. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996; 88(11):4252-8.
43. Seeger K, Kreuzer KA, Lass U, Taube T, Buchwald D, Eckert C, et al. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Res. 2001;61(6):2517-22.
44. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood. 1997;90(2):571-7.
45. Hrusäk O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002;16(7): 1233-58.
46. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007; 21(4):622-6.